RAPT (RAPT Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by RAPT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-02 | Scott Braunstein | Director | A | — | — |
| 2026-02-02 | MARY ANN GRAY | Director | A | — | — |
| 2026-02-02 | Lori Lyons-Williams | Director | A | — | — |
| 2026-02-02 | Michael F Giordano | Director | A | — | — |
| 2026-02-02 | Linda Kozick | Director | A | — | — |
| 2026-02-02 | Ashley L. Dombkowski | Director | A | — | — |
| 2025-06-30 | Ashley L. Dombkowski | Director | A | — | — |
| 2025-06-24 | Dirk G. Brockstedt | CHIEF SCIENTIFIC OFFICER | A | — | — |
| 2025-06-24 | Rodney KB Young | CHIEF FINANCIAL OFFICER | A | — | — |
| 2025-06-24 | Scott Braunstein | Director | A | — | — |
| 2025-06-24 | Brian Russell Wong | PRESIDENT AND CEO | A | — | — |
| 2025-06-24 | WILLIAM HO | CHIEF MEDICAL OFFICER | A | — | — |
| 2025-06-02 | Linda Kozick | Director | A | — | — |
| 2025-06-02 | Lori Lyons-Williams | Director | A | — | — |
| 2025-06-02 | MARY ANN GRAY | Director | A | — | — |
| 2025-06-02 | Michael F Giordano | Director | A | — | — |
| 2025-04-02 | MARY ANN GRAY | Director | A | — | — |
| 2025-04-02 | Wendye Robbins | Director | A | — | — |
| 2025-02-03 | WILLIAM HO | CHIEF MEDICAL OFFICER | A | — | — |
| 2025-02-03 | Dirk G. Brockstedt | CHIEF SCIENTIFIC OFFICER | A | — | — |
| 2025-02-03 | Brian Russell Wong | PRESIDENT AND CEO | A | — | — |
| 2025-02-03 | Rodney KB Young | CHIEF FINANCIAL OFFICER | A | — | — |
| 2024-12-23 | COLUMN GROUP II, LP | — | J | — | — |
| 2024-12-23 | COLUMN GROUP II, LP | — | J | — | — |
| 2024-11-15 | Dirk G. Brockstedt | CHIEF SCIENTIFIC OFFICER | MIXED | — | — |
| 2024-11-15 | Rodney KB Young | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2024-11-15 | Brian Russell Wong | PRESIDENT AND CEO | MIXED | — | — |
| 2024-11-15 | WILLIAM HO | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2024-05-23 | Linda Kozick | Director | A | — | — |
| 2024-05-23 | MARY ANN GRAY | Director | A | — | — |
| 2024-05-23 | Michael F Giordano | Director | A | — | — |
| 2024-05-23 | Lori Lyons-Williams | Director | A | — | — |
| 2024-05-23 | Wendye Robbins | Director | A | — | — |
| 2024-05-23 | WILLIAM JL RIEFLIN | Director | A | — | — |
| 2024-04-01 | WILLIAM JL RIEFLIN | Director | A | — | — |
| 2024-04-01 | Wendye Robbins | Director | A | — | — |
| 2024-04-01 | MARY ANN GRAY | Director | A | — | — |
| 2024-02-01 | WILLIAM HO | CHIEF MEDICAL OFFICER | A | — | — |
| 2024-02-01 | Brian Russell Wong | PRESIDENT AND CEO | A | — | — |
| 2024-02-01 | Rodney KB Young | CHIEF FINANCIAL OFFICER | A | — | — |
| 2024-02-01 | Dirk G. Brockstedt | CHIEF SCIENTIFIC OFFICER | A | — | — |
| 2024-01-08 | Dirk G. Brockstedt | CHIEF SCIENTIFIC OFFICER | Sell | — | — |
| 2024-01-02 | Dirk G. Brockstedt | Chief Scientific Officer | M | — | — |
| 2023-12-22 | WILLIAM HO | Chief Medical Officer | Sell | — | — |
| 2023-11-29 | WILLIAM HO | Chief Medical Officer | Sell | — | — |
| 2023-10-04 | WILLIAM HO | Chief Medical Officer | Sell | — | — |
| 2023-08-22 | WILLIAM HO | Chief Medical Officer | Sell | — | — |
| 2023-08-03 | WILLIAM HO | Chief Medical Officer | M | — | — |
| 2023-06-27 | WILLIAM HO | Chief Medical Officer | M | — | — |
| 2023-05-25 | Linda Kozick | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 375,178 | — |
| — | 10%+ Owner | 375,178 | — |
| — | 10%+ Owner | 326,346 | — |
| — | 10%+ Owner | 326,345 | — |
| — | 10%+ Owner | 324,633 | — |
| — | 10%+ Owner | 243,383 | — |
| — | Director | 193,426 | — |
| — | Director | 175,271 | — |
| — | 10%+ Owner | 175,251 | — |
| — | 10%+ Owner | 160,783 | — |
| — | 10%+ Owner | 69,905 | — |
| — | PRESIDENT AND CEO | 60,500 | — |
| — | Director | 11,840 | — |
| — | Director | 4,956 | — |
| — | Director | 4,956 | — |
| — | Director | 4,956 | — |
| — | Director | 4,956 | — |
| — | Director | 4,956 | — |
| — | Director | 4,956 | — |
| — | CHIEF SCIENTIFIC OFFICER | 3,478 | — |
| — | Director | 2,550 | — |
| — | CHIEF MEDICAL OFFICER | 1,878 | — |
| — | VP, Finance and Controller | 1,592 | — |
| — | CHIEF FINANCIAL OFFICER | 1,260 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RAPT quote page; the site-wide leaderboard is on the insider transactions hub.